About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID
Apoe
apolipoprotein E
MGI:88057
164 phenotypes from 12 alleles in 26 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
Apoeshl/Apoeshl
B6.KOR-Apoeshl
increased circulating cholesterol level J:75488
increased susceptibility to atherosclerosis J:75488
xanthoma J:75488
Apoeshl/Apoeshl
C3.KOR-Apoeshl
increased circulating cholesterol level J:75488
increased susceptibility to atherosclerosis J:75488
xanthoma J:75488
Apoeshl/Apoeshl
C.KOR-Apoeshl
increased circulating cholesterol level J:75488
increased susceptibility to atherosclerosis J:75488
xanthoma J:75488
Apoeshl/Apoeshl
involves: BALB/c * KOR
alopecia J:54051
atherosclerotic lesions J:54051
increased circulating cholesterol level J:54051
premature death J:54051
xanthoma J:54051
Apoeshl/Apoeshl
involves: C3H/He * KOR
alopecia J:54051
atherosclerotic lesions J:54051
increased circulating cholesterol level J:54051
premature death J:54051
xanthoma J:54051
Apoeshl/Apoeshl
involves: C57BL/6 * KOR
alopecia J:54051
atherosclerotic lesions J:54051
increased circulating cholesterol level J:54051
premature death J:54051
xanthoma J:54051
Apoeshl/Apoeshl
KOR-Apoeshl
abnormal nursing J:75488
increased circulating cholesterol level J:75488
increased susceptibility to atherosclerosis J:75488
xanthoma J:75488
Apoeshl/Apoetm1Unc
involves: 129P2/OlaHsd * KOR
increased circulating cholesterol level J:54051
xanthoma J:54051
ApoeTg(rtTA)1Gaga/ApoeTg(rtTA)1Gaga
involves: 129S1/Sv * C57BL/6J
increased circulating cholesterol level J:136987
increased susceptibility to atherosclerosis J:136987
Apoetm1.1Khw/Apoetm1.1Khw
involves: 129S4/SvJae * C57BL/6 * FVB/N
normal homeostasis/metabolism phenotype J:71838
Apoetm1.1Mae/Apoetm1.1Mae
Tg(Fabp4-cre)1Rev/0
B6.Cg-Apoetm1.1Mae Tg(Fabp4-cre)1Rev
decreased cholesterol level J:219838
decreased circulating cholesterol level J:219838
decreased circulating glucose level J:219838
decreased circulating insulin level J:219838
decreased circulating triglyceride level J:219838
decreased epididymal fat pad weight J:219838
decreased liver cholesterol level J:219838
decreased liver triglyceride level J:219838
decreased macrophage cell number J:219838
decreased triglyceride level J:219838
decreased white fat cell lipid droplet size J:219838
decreased white fat cell size J:219838
improved glucose tolerance J:219838
increased cholesterol level J:219838
increased insulin sensitivity J:219838
increased macrophage cell number J:219838
Apoetm1Bres/Apoe+
either: (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * C57BL/6J)
abnormal digestive system physiology J:2809
increased circulating cholesterol level J:2809
Apoetm1Bres/Apoetm1Bres
B6.129P2-Apoetm1Bres
abnormal circulating cholesterol level J:68574
atherosclerotic lesions J:68574
xanthoma J:68574
Apoetm1Bres/Apoetm1Bres
either: (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * C57BL/6J)
abnormal cerebral cortex morphology J:42426
abnormal circulating LDL cholesterol level J:2809
abnormal digestive system physiology J:2809
abnormal hippocampus morphology J:42426
abnormal neuron morphology J:42426
increased circulating cholesterol level J:2809, J:42426
increased circulating VLDL cholesterol level J:2809
increased susceptibility to atherosclerosis J:2809
increased triglyceride level J:2809
Apoetm1Bres/Apoetm1Bres
involves: 129P2/OlaHsd * C57BL/6
atherosclerotic lesions J:29950
increased circulating cholesterol level J:29950
increased susceptibility to atherosclerosis J:43846
xanthoma J:43846
Apoetm1Bres/Apoetm1Bres
involves: 129P2/OlaHsd * C57BL/6 * NIH Black Swiss
atherosclerotic lesions J:42927
decreased circulating HDL cholesterol level J:42927
increased circulating cholesterol level J:42927
increased circulating triglyceride level J:42927
Apoetm1Khw/Apoetm1Khw
involves: 129S4/SvJae * C57BL/6
increased circulating cholesterol level J:75681
increased circulating LDL cholesterol level J:75681
increased circulating triglyceride level J:75681
increased circulating VLDL cholesterol level J:75681
Apoetm1Lmh/Apoe+
involves: 129S7/SvEvBrd * C57BL/6
abnormal lipid homeostasis J:22347
atherosclerotic lesions J:22347
increased circulating cholesterol level J:22347
increased circulating HDL cholesterol level J:22347
increased circulating VLDL cholesterol level J:22347
Apoetm1Lmh/Apoetm1Lmh
involves: 129S7/SvEvBrd * C57BL/6
abnormal lipid homeostasis J:22347
increased circulating cholesterol level J:22347
increased circulating HDL cholesterol level J:22347
increased circulating VLDL cholesterol level J:22347
xanthoma J:24054
Apoetm1Unc/Apoe+
involves: 129P2/OlaHsd * C57BL/6
increased circulating triglyceride level J:16573
Apoetm1Unc/Apoetm1Unc
B6.129P2-Apoetm1Unc
abnormal adrenal cortex morphology J:60585
abnormal adrenal gland morphology J:60585
abnormal adrenal medulla morphology J:60585
abnormal cell-mediated immunity J:125366
abnormal dendritic cell physiology J:125366
abnormal gland physiology J:60585
abnormal kindling response J:118390
abnormal lipid level J:125366
abnormal locomotor behavior J:71062
abnormal myelin sheath morphology J:106368
abnormal response to new environment J:71062
abnormal sciatic nerve morphology J:106368
abnormal spatial learning J:71062
abnormal synaptic vesicle morphology J:118390
abnormal thermal nociception J:106368
atherosclerotic lesions J:61287
decreased brown adipose tissue mass J:60585
decreased circulating leptin level J:60585
decreased epididymal fat pad weight J:60585
decreased exploration in new environment J:60585
decreased startle reflex J:71062
hypersecretion of corticosterone J:60585
hypopituitarism J:60585
increased anxiety-related response J:60585
increased CD4-positive, alpha beta T cell number J:125366
increased circulating cholesterol level J:61287
increased fluid intake J:60585
increased food intake J:60585
increased susceptibility to parasitic infection J:125366
Apoetm1Unc/Apoetm1Unc
B6.129P2-Apoetm1Unc/J
abnormal aorta wall morphology J:101576, J:142083
abnormal B cell activation J:133606
abnormal basilar membrane morphology J:101576
abnormal blood flow velocity J:108154
abnormal blood vessel physiology J:60364
abnormal blood-brain barrier function J:69455
abnormal bone structure J:111209
abnormal CD4-positive, alpha beta T cell number J:47027, J:108154
abnormal circulating cholesterol level J:73202
abnormal cochlea morphology J:101576
abnormal enzyme/coenzyme activity J:73202
abnormal eye electrophysiology J:70245, J:84688
abnormal glomerular capillary thrombosis J:125978
abnormal immune serum protein physiology J:61564
abnormal immune system morphology J:47027
abnormal immune system physiology J:61564
abnormal kidney arterial blood vessel morphology J:125978
abnormal liver physiology J:104609
abnormal lung hysteresivity J:136630
abnormal lung volume J:136630
abnormal osteoblast physiology J:111209
abnormal pulmonary alveolus morphology J:136630
abnormal renal glomerulus morphology J:125978
abnormal retinal inner nuclear layer morphology J:70245
abnormal skeleton physiology J:111209
abnormal spatial learning J:120203
abnormal spiral modiolar artery morphology J:101576
abnormal stria vascularis morphology J:101576
abnormal T cell number J:47027
abnormal tectorial membrane morphology J:101576
arteriosclerosis J:108154
atherosclerotic lesions J:60364, J:73202, J:91058, J:97385, J:101576, J:105736, J:108154, J:142083
blood vessel inflammation J:91058
cardiac hypertrophy J:108154
cochlear ganglion degeneration J:101576
cochlear inner hair cell degeneration J:101576
cochlear outer hair cell degeneration J:101576
deafness J:101576
decreased body length J:136630
decreased body weight J:60364, J:108154
decreased circulating glucose level J:73202
decreased circulating HDL cholesterol level J:91058
decreased circulating homocysteine level J:73202
decreased circulating triglyceride level J:93987
decreased follicular B cell number J:133606
decreased hematocrit J:108154
decreased interferon-gamma secretion J:47027
decreased marginal zone B cell number J:133606
decreased susceptibility to atherosclerosis J:226403
decreased susceptibility to type IV hypersensitivity reaction J:61564
decreased systemic vascular resistance J:108154
decreased vasodilation J:101576
dilated glomerular capillary J:125978
expanded mesangial matrix J:125978
hyperlipidemia J:101576
impaired muscle relaxation J:60364
impaired olfaction J:89344
increased airway resistance J:136630
increased anti-double stranded DNA antibody level J:133606
increased anti-nuclear antigen antibody level J:133606
increased autoantibody level J:133606
increased B cell number J:133606
increased bone mineral density J:111209
increased bone trabecula number J:111209
increased cardiac output J:108154
increased cardiac stroke volume J:108154
increased cholesterol efflux J:226403
increased circulating cholesterol level J:73202, J:91058, J:97385, J:101576, J:104609, J:125978, J:133606
increased circulating HDL cholesterol level J:226403
increased circulating LDL cholesterol level J:91058, J:93987, J:101576
increased circulating triglyceride level J:73202, J:91058, J:101576
increased circulating VLDL cholesterol level J:91058, J:93987, J:101576
increased compact bone thickness J:111209
increased heart weight J:108154
increased IgM level J:61564
increased immunoglobulin level J:133606
increased lung compliance J:136630
increased marginal zone B cell number J:133606
increased or absent threshold for auditory brainstem response J:101576
increased spleen weight J:61564
increased susceptibility to atherosclerosis J:43846, J:101576
increased susceptibility to systemic lupus erythematosus J:133606
increased susceptibility to weight gain J:136630
increased T-helper 2 cell number J:47027
increased thigmotaxis J:120203
kidney microaneurysm J:125978
mesangiolysis J:125978
organ of Corti degeneration J:101576
oxidative stress J:97385
premature death J:73202
renal glomerulus lipidosis J:125978
skin lesions J:73202
spiral modiolar artery stenosis J:101576
thin retinal inner nuclear layer J:70245
thin retinal outer nuclear layer J:70245
vascular stenosis J:101576
xanthoma J:43846, J:73202
Apoetm1Unc/Apoetm1Unc
B6.Cg-Apoetm1Unc Faslpr
increased anti-double stranded DNA antibody level J:133606
increased anti-nuclear antigen antibody level J:133606
increased circulating cholesterol level J:133606
increased immunoglobulin level J:133606
increased susceptibility to atherosclerosis J:133606
increased susceptibility to systemic lupus erythematosus J:133606
Apoetm1Unc/Apoetm1Unc
either: B6.129P2-Apoetm1Unc/J or (involves: 129P2/OlaHsd * C57BL/6J * ICR)
abnormal spatial learning J:100975
normal behavior/neurological phenotype J:100975
decreased vertical activity J:100975
normal nervous system phenotype J:55835, J:100975
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd
abnormal circulating cholesterol level J:48202
abnormal dendrite morphology J:101973
abnormal susceptibility to atherosclerosis J:154332
decreased cerebral infarction size J:133156
decreased vasodilation J:154332
increased anxiety-related response J:101973
increased circulating cholesterol level J:48202
increased circulating corticosterone level J:101973
increased startle reflex J:101973
increased susceptibility to atherosclerosis J:107390
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
atherosclerotic lesions J:66419
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * C57BL/6
abnormal astrocyte physiology J:58019
abnormal synapse morphology J:43043
atherosclerotic lesions J:16573, J:40136, J:41510, J:80689
decreased circulating HDL cholesterol level J:16573
hyperlipidemia J:80689
increased circulating cholesterol level J:16573, J:40136, J:41510, J:80689
increased circulating LDL cholesterol level J:16573
increased circulating triglyceride level J:16573, J:80689
increased circulating VLDL cholesterol level J:16573, J:41510
increased prostaglandin level J:125376
lung inflammation J:83615
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * C57BL/6 * DBA
abnormal cholesterol homeostasis J:75567
abnormal circulating protein level J:75567
abnormal lipid homeostasis J:75567
decreased circulating HDL cholesterol level J:75567
increased circulating cholesterol level J:75567
increased circulating phospholipid level J:75567
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
atherosclerotic lesions J:130658
Apoetm1Unc/Apoetm1Unc
Tg(Cyp21a1-Apoe)614Fet/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
abnormal circulating cholesterol level J:130658
abnormal circulating protein level J:130658
decreased susceptibility to atherosclerosis J:130658
Apoetm1Unc/Apoetm1Unc
Tg(Cyp21a1-Apoe)619Fet/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
abnormal circulating apolipoprotein E level J:130658
abnormal lipid level J:130658
decreased susceptibility to atherosclerosis J:130658
increased circulating cholesterol level J:130658
Apoetm2(APOE_i2)Sfu/Apoetm2(APOE_i2)Sfu
involves: 129P2/OlaHsd
abnormal response to CNS ischemic injury J:104859
decreased circulating cholesterol level J:104859
Apoetm4Mae/Apoetm4Mae
129S6/SvEvTac-Apoetm4Mae
abnormal circulating lipid level J:172417
decreased body weight J:172417
decreased susceptibility to atherosclerosis J:172417
increased circulating cholesterol level J:172417
increased circulating HDL cholesterol level J:172417
increased circulating triglyceride level J:172417
increased circulating VLDL cholesterol level J:172417
Tg(Cyp21a1-Apoe)614Fet/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
increased circulating cholesterol level J:130658
Tg(Cyp21a1-Apoe)619Fet/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
increased circulating cholesterol level J:130658

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/23/2021
MGI 6.16
The Jackson Laboratory